HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

protein kinase modulator

Subscribe to New Research on protein kinase modulator

stimulates phosphorylation of histones by mammalian cGPK & inhibits phosphorylation by cAPK; stimulates & inhibits protein kinase; see also records for PKIbeta and PKIgamma

Also Known As:

PKA inhibitor; cAMP-dependent protein kinase protein modulator; cGK Ibeta; cGKIbeta; cGMP-dependent protein kinase protein modulator; cyclic AMP-dependent protein kinase inhibitor; megamodulin; protein kinase inhibitor type I; protein kinase stimulatory modulator

Networked: 51 relevant articles (1 outcomes, 3 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 58343
  - Intracellular Signaling Peptides and Proteins: 17
    - protein kinase modulator: 51
- Peptides: 16238
  - Intracellular Signaling Peptides and Proteins: 17
    - protein kinase modulator: 51

Experts

1.	Neugebauer, Volker: 2 articles (10/2009 - 04/2008)
2.	Lin, Hsun-Hsun: 1 article (11/2009)
3.	Lai, Chih-Chia: 1 article (11/2009)
4.	Chiu, Hong-Yi: 1 article (11/2009)
5.	Zhang, Pei-Hua: 1 article (10/2009)
6.	Yan, Xi-Sheng: 1 article (10/2009)
7.	Ma, Ji-Hua: 1 article (10/2009)
8.	Ji, Guangchen: 1 article (10/2009)
9.	Tanabe, Mitsuo: 1 article (06/2009)
10.	Takasu, Keiko: 1 article (06/2009)

Related Diseases

1.	Infection 06/01/2003 - "Infection of HMEC with replication-deficient adenovirus containing the protein kinase A inhibitor gene (PKA inhibitor) blocked both the FI-mediated protective effects on RhoA activation and resistance changes. " 02/14/1997 - "Concordant with the activation of CFTR by only cGK II, infection with Ad-cGK II but not Ad-cGK Ibeta enabled cGMP analogs to increase CFTR phosphorylation in intact cells. " 02/14/1997 - "In contrast, infection with recombinant adenoviruses expressing cGK Ibeta or luciferase did not convey cGMP sensitivity to CFTR in IEC-CF7 cells. " Order ALL the reference details at left...
2.	Anoxia (Hypoxia) 12/01/2002 - "This may be mediated via a protein kinase A-dependent mechanism, as treatment of cells with Br-cAMP (100 microM) mimicked chronic hypoxia in increasing PDE3A expression, while the PKA inhibitor, H8 peptide (50 microM) abolished the hypoxic-dependent increase in PDE3A transcript. " 06/01/2005 - "Moreover, PKA inhibitor H89 abolished IHA hypoxia-induced increase in Ser(16) phosphorylation, Ca(2+)-pump ATPase activity, and the recovery of cardiac performance after ischemia. " 02/01/1997 - "These results were confirmed by using the protein kinase A (PKA) activator Sp-cAMPS and the PKA inhibitor Rp-cAMPS: while Sp-cAMPS was synergistic with hypoxia on the HIF-1 DNA recognition site, the Rp-cAMPS isomer showed no effect. " 04/01/2008 - "We also found that forskolin (a direct adenylate cyclase activator) can mimic the action of hypoxia on the production of MMP-9 by DCs, whereas the adenylate cyclase inhibitor SQ22536 and the PKA inhibitor H89 can abrogate the inhibition of MMP-9 produce by mDCs under hypoxia. " 09/01/1998 - "A protein kinase A (PKA) inhibitor (H89, 20 micromol/l) suppressed hypoxia-induced GLUT1 mRNA expression by 42 +/- 9% (P < 0.01). " Order ALL the reference details at left...
3.	Seizures (Seizure) 05/01/2005 - "In this study, we determined PKA enzymatic activity in the rat hippocampus during picrotoxin-induced seizures, using H-9 dihydrochloride, a PKA inhibitor, to investigate the in vivo effects of this enzyme on seizures induced by picrotoxin microdialysis in the rat hippocampus. " Order ALL the reference details at left...
4.	Amnesia (Dissociative Amnesia) 03/01/2002 - "On the contrary, no effect of the PKA inhibitor was found with an immediately posttraining injection and amnesia was observed only when training was shortened from 15 to 12 trials (training duration from 45 to 36 min). " 03/01/2002 - "In the context-signal learning paradigm of the crab Chasmagnathus, the protein kinase (PKA) activator Sp-5,6-DCl-cBIMPS facilitated long-term memory (LTM) induced by spaced training while the PKA inhibitor 8-chloroadenosine-3', 5'-monophosphorothioate, Rp-isomer (Rp-8-Cl-cAMPS) produced amnesia. " Order ALL the reference details at left...
5.	Ischemia 01/01/2002 - "The ischemia-induced increase in Ser(16)phosphorylation was significantly diminished in hearts from catecholamine-depleted animals and/or after beta-blockade and abolished in the presence of the PKA-inhibitor, H-89. " 04/01/2005 - "We hypothesized that the ischemia-induced activation of cAMP-dependent protein kinase A (PKA), could beneficially be inhibited by a PKA-inhibitor N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinoline-sulfonamide (H-89). " 06/01/2005 - "Moreover, PKA inhibitor H89 abolished IHA hypoxia-induced increase in Ser(16) phosphorylation, Ca(2+)-pump ATPase activity, and the recovery of cardiac performance after ischemia. " 10/01/2004 - "The effects of IPC on calpain, alpha-fodrin, and LDH release were blunted by the application of the PKA inhibitor H89 or alprenolol during IPC, while transient stimulation of PKA with CPT-cAMP or isoproterenol before ischemia attenuated calpain activation, alpha-fodrin degradation, and markedly reduced LDH release (P<0.001). " 06/01/2005 - "METHODS: After 6-hydroxydopamine (6-OHDA) pretreatment and a 20-min stabilization period, hearts were perfused at constant pressure for 20 min then subjected to 40 min of global ischemia and 30 min of reperfusion (I/R, Ctrl); exposed to 0.01 microM XA for 5 min with or without 10 microM atenolol (ATE), a specific antagonist of beta1-AR, followed by a 15-min XA-free perfusion before I/R (PC, ATE-PC, respectively); treated during 20 min with either phosphoinositide (PI) 3-kinase inhibitors, LY-294002 (LY, 15 microM), or wortmaninn (WO, 0.1 microM); protein kinase C (PKC) inhibitor, GF-109203X (GF, 4 nM); or protein kinase A (PKA) inhibitor, H89 (H89, 1 microM), with an infusion starting 3 min before XA (LY-PC, WO-PC, GF-PC, and H89-PC, respectively). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)
2.	H 89 (h89)
3.	Staphylococcal Protein A (A, Protein)
4.	Phosphotransferases (Kinase)
5.	Calcium-Calmodulin-Dependent Protein Kinase Type 2
6.	Picrotoxin
7.	bisindolylmaleimide
8.	KT 5823
9.	KN 93
10.	KN 62

Related Therapies and Procedures

1.	Radiotherapy

blog comments powered by Disqus

TREATMENT OPTIONS
for Infection,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 14545 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>